WO2005061222A1 - Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids - Google Patents
Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids Download PDFInfo
- Publication number
- WO2005061222A1 WO2005061222A1 PCT/DK2004/000890 DK2004000890W WO2005061222A1 WO 2005061222 A1 WO2005061222 A1 WO 2005061222A1 DK 2004000890 W DK2004000890 W DK 2004000890W WO 2005061222 A1 WO2005061222 A1 WO 2005061222A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- container
- container according
- filled
- less
- water
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
- B32B27/322—Layered products comprising a layer of synthetic resin comprising polyolefins comprising halogenated polyolefins, e.g. PTFE
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/40—Properties of the layers or laminate having particular optical properties
- B32B2307/412—Transparent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/726—Permeability to liquids, absorption
- B32B2307/7265—Non-permeable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/80—Medical packaging
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2323/00—Characterised by the use of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Derivatives of such polymers
- C08J2323/02—Characterised by the use of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Derivatives of such polymers not modified by chemical after treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S206/00—Special receptacle or package
- Y10S206/828—Medicinal content
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1334—Nonself-supporting tubular film or bag [e.g., pouch, envelope, packet, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
Definitions
- Some medicaments are delivered to the patients in solid form, other in liquid form. Often, the liquid medicaments are delivered in a container. Some containers consist only or mainly of glass, other consist only or mainly of other materials such as plastic. Medicaments in solid form are often marketed in a glass container or a plastic container. An example of a plastic container is a blister package.
- a pharmaceutical composition in liquid form the active ingredient is present in dissolved or suspended form.
- a pharmaceutical composition may contain a pharmaceutically active carrier, a disintegrator, a stabilizer, or a buffer substance. The route of administration varies between the different medicaments.
- Some medicaments are administered via the oral route, other are administered by injecting the me- dicament to the patient, for example, intravenously or subcutaneously.
- Many medicaments being peptides, for example, insulin and growth hormone, are administered by injections.
- syringes were used for the injections.
- insulin it is becoming more and more common to use so called pen systems for the injections.
- pumps for administration by injection may become a popular way of administrations by injections.
- the aqueous composition will be present in a glass reservoir or another hard reservoir, in other pumps, aqueous compositions will be present in a flexible reservoir, for example a reservoir which is wholly or mainly made of another material than glass, for example of plastic.
- a main task for the inventors of this invention has been to find a material which can be used to prepare a transparent, flexible container fulfilling the safety requirements for storage of pharmaceutical solutions containing a preservative such as phenol, m-cresol and benzyl alcohol. It was extremely difficult to find a material fulfilling these requirements.
- the object of this invention is to overcome or ameliorate at least some of the disadvantages of the prior art. Hence, not all the objects mentioned below may be fully overcome or ameliorated.
- a more specific object of this invention is to furnish a container or reservoir. Another object of this invention is to furnish a flexible container. Another object of this invention is to furnish a transparent container. Another object of this invention is to furnish a part allowing sterilization. Another object of this invention is to furnish a material which may be welded to itself to form the above mentioned reservoir. Another object of this invention is to furnish a container which can be used for stor- age of liquid solutions or suspensions of medicaments, optionally containing preservatives.
- Another object of this invention is to furnish a container which has a sufficient transparency so as to enable inspection of the content of the container.
- Another object of this invention is to furnish a container which can be used to storage of liquid solutions or suspensions of medicaments, optionally containing preservatives and which container not or only to a minor degree consists of glass.
- Another object of this invention is to furnish a container having barrier properties securing that the concentration of the active ingredient in the aqueous composition is not changed substantially during storage for a sufficient period of time.
- Another object of this invention is to furnish a container having barrier properties se- curing that the concentration of any preservative present in the aqueous composition is not changed substantially during storage for a sufficient period of time.
- a further object of this invention is to furnish a film for a pouch which can be used for storage of sterile water based drug formulation.
- a further object of this invention is to furnish a film material for said pouch fulfilling certain functional requirements such as physical properties for the material after sterilization, chemical requirements for the material after sterilization, and cleanliness.
- one object of this invention is to furnish a film material for said pouch which can be sterilized, for example, using gamma irradiation, electron beam, steam, or ethylene oxide.
- a further object of this invention is to furnish a film material for said pouch which, after sterilization, fulfils most of or all the following physical requirements: 1 ) the material must be transparent, 2) the material must provide a good barrier against water; 3) the mate- rial must provide a good barrier against gasses (for example, oxygen and carbon dioxide); 4) the material must provide a good barrier against preservatives (for example, phenol and meta-cresol); 5) the material must provide a good barrier against odors (for example preservatives); 6) the material must be resistant against environmental stress cracking (for example, oils, perfumes); 7) the material must be resistant against flex-crack; 8) the material must have good sealing properties (for example, by welding); and 9) the material must not relax significantly during storage and use.
- the material must be transparent, 2) the material must provide a good barrier against water; 3) the mate- rial must provide a good barrier against gasses (for example, oxygen and carbon dioxide); 4) the material must provide a good barrier against preservative
- a further object of this invention is to furnish a film material for said pouch which, after sterilization, fulfils most of or all the following chemical requirements: 1) the material must not emit substances to the drug which can affect the health and safety of the patient (leachables); 2) the material must have a very low level of extractables; and 3) the material must be compatible with the drug formulation.
- a further object of this invention is to furnish a film material for said pouch which, after sterilization, fulfils the following requirements for cleanliness: 1) it shall be possible to prepare the material under hygienic conditions; and 2) the final product must be free of dust and particles.
- a further object of this invention is to furnish a film for said pouch fulfilling certain health and safety requirements, preferably most of or all the requirements mentioned in 1 ) European Pharmacopoeia (Ph. Eur.) 2002, 4 edition; 2) The United States Pharmacopeia (USP) 25; 3) Japanese Pharmacopeia (JP) XIV; 4) EEC Directive 90/128 + amendments "Relating to plastics materials and articles intended to come into contact with foodstuffs"; 5) Code of federal regulations (CFR) Title 21 Food and Drugs, part 170 - 190; 6) HI/9090/90 EN. Plastic Primary Packaging Materials. Note for Guidance; and 7) Guidance for Industry. Container Closure Systems for Packaging Human Drugs and Biologies, Chemistry, Manufacturing, and Controls Documentation. FDA, May 1999. DEFINITIONS
- a flexible item is an item that can bend or be bend easily and which does not break (unless it is bend too much). Glass is not flexible.
- the term flexible in connection with the containers indicates that if the container is subjected to a force, for example, by being filled with a liquid, it will change its form without breaking.
- insulin refers to insulin from any species such as porcine insulin, bovine insulin, and human insulin and salts thereof such as zinc salts, and protamin salts as well as active derivatives of insulin, and insulin analogues.
- active derivatives of insulin is what a skilled art worker generally considers derivatives, vide general textbooks, for example, insulin having a substituent not present in the parent insulin molecule.
- insulin analogues refers to insulin wherein one or more of the amino acid residues have been exchanged with another amino acid residue and/or from which one or more amino acid residue has been deleted and/or from which one or more amino acid residue has been added with the proviso that said insulin analogue has a sufficient insulin activity.
- free fat cell assay any skilled art worker, for example, a physician, knows when and which dosages to administer of the insulin analogue. Examples of insulin analogues are described in the following patents and equivalents thereto: US 5,618,913, EP 254,516, EP 280,534, US 5,750,497, and US 6,011,007.
- insulin analogues examples include insulin aspart (i.e., Asp 628 human insulin), insulin lispro (i.e., Lys B28 ,Pro B29 human insulin), and insulin glargin (i.e., Gly A21 ,Arg B31 ,Arg B32 human insulin).
- insulin also covers compounds which can be considered being both an insulin derivative and an insulin analogue. Examples of such compounds are described in the following patents and equivalents thereto: US 5,750,497, and US 6,011 ,007.
- An example of a specific insulin analogue and derivative is insulin detemir (i.e., des-Thr B30 human insulin ⁇ Lys B29 tetradecanoyl).
- PE consists of at least 75%, preferably at least 90 %, more preferred at least 95 %, (weight/weight) of polyethylene.
- PP consists of at least 75%, preferably at least 90 %, more preferred at least 95 %, (weight/weight) of polypropylene.
- PE is as defined in European Pharmacopoeia 2001 , 4 lh Edition, point 3.1.5, the content of which is hereby incorporated by reference. Examples of components present in PE are higher alkene homologues (C 3 to C 10 ) and other additives mentioned therein.
- PP is as defined in European Pharmaco- poeia 2001 , 4 th Edition, point 3.1.6, the content of which is hereby incorporated by reference.
- PP consists of the homopolymer of propylene or of a copolymer of propylene with not more than 25% of ethylene or a mixture (alloy) of polypropylene with not more than 25 % of polyethylene. It may contain additives, vide the above point 3.1.6.
- Fig. 3 shows one side of the flexible container.
- the welding layer 4 secures that the container is tight.
- the inner of the container 5 may be filled with a liquid.
- Fig. 4 is a view taken at the line 1—1 in Fig. 3 perpendicular to the surface shown in Fig. 3.
- the wall of the container 6 is welded together.
- this invention relates to a flexible, transparent, water-tight chamber comprised of a PCTFE film wherein said film is formed into a transparent pouch and wherein the pouch is sufficiently moisture proof, phenol proof and m-cresol proof to allow for extended storage of a medicament containing water, phenol and/or m-cresol without significant changes in concentration of water, phenol, and m-cresol occurring over the extended time period and wherein the pouch is radiation stehlisable.
- a container described in the claims below fulfills the requirements set to a container which is to be used for storage of an aqueous solution.
- this invention relates to a flexible, at least partially transparent container for storage of a liquid in a water-tight chamber, the wall material of which chamber comprises a PCTFE monolayer, characterized in that when said chamber is filled with water and when it is stored at a temperature of about 5°C for 2 years less than 10 % (weight/weight) of the content of water diffuses out from the container; and when said chamber is filled with water containing about 1.8 mg/mL (19 mM) of phenol and when it is stored at a temperature of about 5°C for 24 months, the change in the concentration of phenol in the liquid is less than about 10 %.
- this invention relates to a flexible, at least partially transparent container for storage of a liquid in a water-tight chamber, the wall material of which chamber comprises a PCTFE monolayer, characterized in that when said chamber is filled with water and when it is stored at a temperature of about 5°C for 2 years less than 10 % (weight/weight) of the content of water diffuses out from the container; and when said chamber is filled with water containing 2.06 mg/mL (19 mM) of m-cresol and when stored at a temperature of about 5°C for 24 months, the change in the concentration of m-cresol is less than about 10 %.
- this invention relates to a flexible, at least partially transparent container for storage of a liquid in a water-tight chamber, the wall material of which chamber comprises a PCTFE monolayer, characterized in that when said chamber is filled with water and when it is stored at a temperature of about 5°C for 2 years less than 10 % (weight/weight) of the content of water diffuses out from the container; and when said chamber is filled with water containing 2.06 mg/mL (19 mM) of m-cresol and when stored at a temperature of about 37°C for 12 weeks, the change in the concentration of m-cresol is less than about 10 %.
- this invention relates to a container as described above, wherein the layer is weldable. In another embodiment, this invention relates to a container as described above, which is at least partially transparent. In another embodiment, this invention relates to a container as described above, which is wholly transparent.
- this invention relates to a container as described above, which is prepared from a pouch foil which when tested by test A described herein gives a change in the pH value which is than about +/- 0.2.
- this invention relates to a container as described above, which is prepared from a pouch foil which when tested by test C described herein gives a maximum weight loss of 2.5%, preferably not more than about 2%.
- this invention relates to a container as described above, which is prepared from a pouch foil which when tested by test C described herein gives a maximum loss of m-cresol of about 10%, preferably not more than about 5%.
- this invention relates to a container as described above, which is prepared from a pouch foil which when tested by test C described herein gives a maximum loss of phenol of about 10%, preferably not more than about 5%.
- this invention relates to a container as described above, which is prepared from a pouch foil which when tested by test C described herein gives a change in the pH value which is not more than about +/- 0.2.
- this invention relates to a container as described above, which is prepared from a pouch foil which fulfills test D described herein for the dilution 1 :50, preferably the dilution 1 :100, more preferred the dilution 1 :200, even more preferred the dilution 1 :400.
- this invention relates to a container as described above, which container, when completely filled with liquid, can contain an amount of liquid which is at least about 0.5 ml, preferably at least about 1 ml, and not more than about 10 ml, preferably not more than about 5 ml, more preferred not more than about 3 ml and, preferably, the volume is about 2.5 ml.
- this invention relates to a use of a container as described above for storing a liquid pharmaceutical composition mentioned in any of the preceding claims.
- this invention relates to a container as described above filled partially or wholly with a liquid pharmaceutical composition.
- this invention relates to a container as described above filled partially or wholly with a liquid pharmaceutical composition wherein the active ingredient is a peptide.
- this invention relates to a container as described above wherein the peptide is insulin.
- the active ingredient in said pharmaceutical composition is growth hormone or factor VII and analogs thereof.
- this invention relates to a container as described above wherein the content of insulin is in the range from about 10 U/ml to about 1500 U/ml.
- this invention relates to a container as described above containing a preservative.
- this invention relates to a container as described above filled partially or wholly with a liquid pharmaceutical composition containing phenol.
- this invention relates to a container as described above filled partially or wholly with a liquid pharmaceutical composition containing m-cresol. In another embodiment, this invention relates to a container as described above filled partially or wholly with a liquid pharmaceutical composition containing benzyl alcohol.
- this invention relates to a PCTFE film, characterized in that the film material can be used for preparing a transparent container as described above.
- the container according to this invention must have a flexibility which allows filling of the container so that it can be used as a pouch. If the aqueous composition contains a preservative it is important that the concentra- tion thereof is sufficient to maintain an antimicrobiological efficacy.
- the known PCTFE containers cannot be used for storing of medicaments containing preservatives such as phenol, m-cresol or benzyl alcohol.
- the container of this invention does not have an adhesive layer.
- the container of this invention is sealed by welding.
- the container of this invention consists of a PCTFE material which enables sterilization of the container in a convenient way, for example, by ⁇ or ⁇ irradiation or by heating.
- the container of this invention consists of a PCTFE material which fulfills the following test for flexibility: Two rectangular pieces of the material being tested both having the size 60 mm x 20 mm are welded together with a 3 mm welding zone forming a welded test pouch and, thereafter, 1.5 ml of water is filled into the pouch. If the overpressure is below 100 mBar, the material has a sufficient flexibility.
- the container of this invention consists of a PCTFE material which fulfills the following test for flexibility: Two rectangular pieces of the material being tested both having the size 60 mm x 20 mm are welded together with a 2 mm welding zone forming a welded test pouch and, thereafter, 1.5 ml of water is filled into the pouch.
- the container of this invention is to be used for storage of an aqueous pharmaceutical composition.
- the active ingredient in said pharmaceutical composition is a protein.
- the active ingredient is insulin or growth hormone.
- the amount of insulin in the aqueous solution is in the range with the lower limit being 10 U/ml, preferably 40 U/ml, more preferred 100 U/ml, and even more preferred 150 U/ml, and the upper limit being 1500 U/ml, preferably 1000 U/ml, more preferred 500 U/ml, even more preferred 300 U/ml.
- the amount of phenol in the aqueous solution is in the range from about 15 to about 25 mM. In another preferred embodiment of this invention, the amount of m-cresol in the aqueous solution is in the range from about 15 to about 25 mM. In another preferred embodiment of this invention, the amount of benzyl alcohol in the aqueous formulation is in the range from about 15 to about 25 mM. In another preferred embodiment of this invention, there is no benzyl alcohol present in the aqueous formulation.
- the container of this invention may be equipped with a device whereby said liquid can be expelled from said container (when desired).
- a device whereby said liquid can be expelled from said container (when desired).
- An example of such a device can be a septum for needle penetration in the form of a rubber material adhered to the inside or the outside of the container foil or in the welding zone between the two foils.
- Another example can be an active or a passive closure valve adhered to the container.
- the container of this invention may be emptied by application on external pressure to the reservoir or by suction from a pump device.
- the container of this invention can be used in many devices, for example, a pump, a syringe, or a pen like syringe. Conveniently, the container of this invention is disposable.
- the container of this invention is prepared from pouch foils fulfilling some or all of the following tests:
- the immersed sample and a reference sample are placed in an incubator at 37°C for 1 week.
- the content of m-cresol in the solution is analyzed by using a chromatographic method. This test will show the total migration of m-cresol including the absorption directly into the edge.
- the maximum loss of m-cresol should be 10% and preferred less than 5%.
- the pH value of the solution should not change more than +/- 0.2.
- a foil in test is placed between two flanges allowing 10 cm 2 of the foil to be in contact with 5 ml of a solution containing phenokabout 1.80 mg/mL (19 mM), m-cresol: 2.06 mg/mL (19 mM), glycerol:16.0 mg/mL (174 mM), disodiumhydrogenphosphat:1.25 mg/mL (7 mM), sodium chloride: 0.58 mg/mL (10 mM), and pH: 7.40.
- the Paddington cup is placed upside down allowing direct contact between the solution and the foil in an incubator at 37°C and a relative humidity of max. 15% for 1 week along with a reference sample consisting of a Paddington cup with an inert aluminum foil.
- the Paddington cups are weighed before and after the storage.
- the content of m-cresol is analyzed by using a chromatographic method. This test is useful to test the total evaporation and will show the barrier properties against preservatives like m-cresol and phenol.
- the maximum weight loss should be 2.5% preferred less than 1 %
- the maximum loss of m-cresol should be 10% and preferred less than 5%
- the pH value should not change more than +/- 0.2.
- pouches are produced by welding the foil and by filling the pouches with vehicle. Some pouches are weighed before storage at 37°C and a relative humidity of 15% and weighed after up till 12 weeks. Some pouches are stored at 37°C and tested for content of m- cresol and phenol at regular intervals up to 12 weeks. Glass vials are used as a reference.
- the maximum weight loss shall be not more than 2.5%, preferred not more than 2%
- the maximum loss of m-cresol shall be not more than 10% and preferred not more than 5%
- the maximum loss of phenol shall be not more than 10% and preferred not more than 5%.
- the pH value should not change more than +/- 0.2.
- a filled pouch must fulfill the transparency requirement in the European Pharmacopoeia 2001 , 4 th Edition, part 3.2.2.1 concerning plastic containers for aqueous solutions for par- enteral infusion.
- solution S is diluted 1 :200 (for PE or PP) or 1 :400 for other containers.
- This test can be modified by testing solution S diluted 1 :50 or 1 :100.
- Example 1 A PCTFE foil having a thickness of 55 ⁇ m is welded at a temperature of 300°C at a pressure of 3.5 bar for 4 seconds to form a container with the size 60 mm x 20 mm having a welding seam width of 2 mm.
- Test A on the foil The loss of m-cresol was 0.2%. The pH value changed from 7.44 to 7.43.
- Test B on the foil The loss of m-cresol was 0%. The weight loss was 0%. The pH value changed from 7.44 to 7.40.
- Test D on the foil Fulfils the requirements, both in 1 :200 and 1 :400 dilutions.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Bag Frames (AREA)
- Wrappers (AREA)
- Laminated Bodies (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006545920A JP2007515235A (en) | 2003-12-22 | 2004-12-20 | Transparent, flexible and impervious plastic container for storing medicinal fluids |
EP04803041A EP1699629B1 (en) | 2003-12-22 | 2004-12-20 | Transparent, flexible , impermeable plastic container for storage of pharmaceutical liquids |
AT04803041T ATE483580T1 (en) | 2003-12-22 | 2004-12-20 | CLEAR, FLEXIBLE, WATERPROOF PLASTIC CONTAINER FOR STORING PHARMACEUTICAL LIQUIDS |
DE602004029496T DE602004029496D1 (en) | 2003-12-22 | 2004-12-20 | CONTAINER FOR STORING PHARMACEUTICAL LIQUIDS |
US11/472,831 US7807242B2 (en) | 2003-12-22 | 2006-06-22 | Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301916 | 2003-12-22 | ||
DKPA200301916 | 2003-12-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/472,831 Continuation US7807242B2 (en) | 2003-12-22 | 2006-06-22 | Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005061222A1 true WO2005061222A1 (en) | 2005-07-07 |
Family
ID=34707209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2004/000890 WO2005061222A1 (en) | 2003-12-22 | 2004-12-20 | Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids |
Country Status (7)
Country | Link |
---|---|
US (1) | US7807242B2 (en) |
EP (1) | EP1699629B1 (en) |
JP (1) | JP2007515235A (en) |
CN (1) | CN1898087A (en) |
AT (1) | ATE483580T1 (en) |
DE (1) | DE602004029496D1 (en) |
WO (1) | WO2005061222A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007099120A1 (en) | 2006-02-28 | 2007-09-07 | Novo Nordisk A/S | A method and an apparatus for sterilizing packaging material |
WO2008041644A1 (en) * | 2006-09-29 | 2008-04-10 | Daikin Industries, Ltd. | Fuel tank |
US11191722B2 (en) | 2013-04-03 | 2021-12-07 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1791511A (en) * | 2003-06-27 | 2006-06-21 | 诺沃挪第克公司 | High moisture barrier container for medical liquid compositions |
US9139351B2 (en) | 2007-12-11 | 2015-09-22 | Tokitae Llc | Temperature-stabilized storage systems with flexible connectors |
US9174791B2 (en) | 2007-12-11 | 2015-11-03 | Tokitae Llc | Temperature-stabilized storage systems |
US8069680B2 (en) * | 2007-12-11 | 2011-12-06 | Tokitae Llc | Methods of manufacturing temperature-stabilized storage containers |
US8485387B2 (en) * | 2008-05-13 | 2013-07-16 | Tokitae Llc | Storage container including multi-layer insulation composite material having bandgap material |
US8377030B2 (en) * | 2007-12-11 | 2013-02-19 | Tokitae Llc | Temperature-stabilized storage containers for medicinals |
US8603598B2 (en) * | 2008-07-23 | 2013-12-10 | Tokitae Llc | Multi-layer insulation composite material having at least one thermally-reflective layer with through openings, storage container using the same, and related methods |
US8211516B2 (en) | 2008-05-13 | 2012-07-03 | Tokitae Llc | Multi-layer insulation composite material including bandgap material, storage container using same, and related methods |
US8215835B2 (en) | 2007-12-11 | 2012-07-10 | Tokitae Llc | Temperature-stabilized medicinal storage systems |
US9140476B2 (en) | 2007-12-11 | 2015-09-22 | Tokitae Llc | Temperature-controlled storage systems |
US8887944B2 (en) | 2007-12-11 | 2014-11-18 | Tokitae Llc | Temperature-stabilized storage systems configured for storage and stabilization of modular units |
US9205969B2 (en) | 2007-12-11 | 2015-12-08 | Tokitae Llc | Temperature-stabilized storage systems |
PL2349324T3 (en) | 2008-10-17 | 2018-02-28 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
ES2452519T3 (en) | 2009-05-13 | 2014-04-01 | Sio2 Medical Products, Inc. | Container holder |
US9458536B2 (en) | 2009-07-02 | 2016-10-04 | Sio2 Medical Products, Inc. | PECVD coating methods for capped syringes, cartridges and other articles |
ES2534191T3 (en) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
RU2573995C2 (en) | 2009-11-13 | 2016-01-27 | Санофи-Авентис Дойчланд Гмбх | Pharmaceutical composition containing glp-1 agonist and methionine |
US9372016B2 (en) | 2013-05-31 | 2016-06-21 | Tokitae Llc | Temperature-stabilized storage systems with regulated cooling |
US9447995B2 (en) | 2010-02-08 | 2016-09-20 | Tokitac LLC | Temperature-stabilized storage systems with integral regulated cooling |
US11624115B2 (en) | 2010-05-12 | 2023-04-11 | Sio2 Medical Products, Inc. | Syringe with PECVD lubrication |
AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
US8235209B2 (en) | 2010-08-11 | 2012-08-07 | Boston Scientific Scimed, Inc. | Medical device packaging and methods for preparing and packaging medical devices |
SG187904A1 (en) | 2010-08-30 | 2013-04-30 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
JP6013717B2 (en) * | 2010-09-30 | 2016-10-25 | 積水メディカル株式会社 | Protein solution which can be stored in liquid and method for storing protein solution in liquid |
US9878101B2 (en) | 2010-11-12 | 2018-01-30 | Sio2 Medical Products, Inc. | Cyclic olefin polymer vessels and vessel coating methods |
US9096368B2 (en) | 2011-01-19 | 2015-08-04 | Boston Scientific Scimed, Inc. | Medical device packaging and methods for preparing and packaging medical devices |
US8973748B2 (en) | 2011-01-19 | 2015-03-10 | Boston Scientific Scime, Inc. | Medical device packaging and methods for preparing and packaging medical devices |
US9272095B2 (en) | 2011-04-01 | 2016-03-01 | Sio2 Medical Products, Inc. | Vessels, contact surfaces, and coating and inspection apparatus and methods |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
PL2750699T3 (en) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US11116695B2 (en) | 2011-11-11 | 2021-09-14 | Sio2 Medical Products, Inc. | Blood sample collection tube |
JP6095678B2 (en) | 2011-11-11 | 2017-03-15 | エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド | Passivation, pH protection or slippery coatings for pharmaceutical packages, coating processes and equipment |
US9068565B2 (en) | 2012-05-03 | 2015-06-30 | Becton, Dickinson And Company | Container and method for storing a pharmaceutical agent |
EP2846755A1 (en) | 2012-05-09 | 2015-03-18 | SiO2 Medical Products, Inc. | Saccharide protective coating for pharmaceutical package |
WO2014071061A1 (en) | 2012-11-01 | 2014-05-08 | Sio2 Medical Products, Inc. | Coating inspection method |
US9903782B2 (en) | 2012-11-16 | 2018-02-27 | Sio2 Medical Products, Inc. | Method and apparatus for detecting rapid barrier coating integrity characteristics |
US9764093B2 (en) | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
BR112015012470B1 (en) | 2012-11-30 | 2022-08-02 | Sio2 Medical Products, Inc | PRODUCTION METHOD OF A MEDICAL DRUM FOR A MEDICAL CARTRIDGE OR SYRINGE |
WO2014134577A1 (en) | 2013-03-01 | 2014-09-04 | Sio2 Medical Products, Inc. | Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus |
CN110074968B (en) | 2013-03-11 | 2021-12-21 | Sio2医药产品公司 | Coated packaging material |
US9937099B2 (en) | 2013-03-11 | 2018-04-10 | Sio2 Medical Products, Inc. | Trilayer coated pharmaceutical packaging with low oxygen transmission rate |
US20160017490A1 (en) | 2013-03-15 | 2016-01-21 | Sio2 Medical Products, Inc. | Coating method |
US20140370211A1 (en) * | 2013-06-14 | 2014-12-18 | Prolamina Midwest Corporation | Carbon dioxide gas permeable packaging film |
WO2015148471A1 (en) | 2014-03-28 | 2015-10-01 | Sio2 Medical Products, Inc. | Antistatic coatings for plastic vessels |
PE20171622A1 (en) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
US11077233B2 (en) | 2015-08-18 | 2021-08-03 | Sio2 Medical Products, Inc. | Pharmaceutical and other packaging with low oxygen transmission rate |
EP3804686B1 (en) * | 2017-10-10 | 2023-08-30 | Sun Pharmaceutical Industries Ltd | Intravenous infusion dosage form for pemetrexed |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54103184A (en) * | 1978-01-27 | 1979-08-14 | Toppan Printing Co Ltd | Bag for freezing preservation |
EP0254516A2 (en) | 1986-07-21 | 1988-01-27 | Novo Nordisk A/S | Novel Peptides |
EP0280534A2 (en) | 1987-02-25 | 1988-08-31 | Novo Nordisk A/S | Novel insulin derivatives |
WO1993006159A1 (en) * | 1991-09-27 | 1993-04-01 | Allied-Signal Inc. | Barrier film |
US5618913A (en) | 1985-08-30 | 1997-04-08 | Novo Nordisk A/S | Insulin analogues |
US5750497A (en) | 1993-09-17 | 1998-05-12 | Novo Nordisk A/S | Acylated insulin |
US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
DE19850607A1 (en) * | 1998-11-03 | 2000-05-04 | Rolf Siegel | Container for liquids containing biologically active substances, cells or cell organelles comprises a flexible container sealed within a rigid container |
EP0898466B1 (en) * | 1996-05-13 | 2001-12-12 | B. Braun Medical, Inc. | Flexible, multiple-compartment drug container and method of making |
EP1258234A1 (en) * | 2000-02-24 | 2002-11-20 | Mitsubishi Shoji Plastics Corporation | Plastic container for liquid medicine |
WO2005000580A1 (en) * | 2003-06-27 | 2005-01-06 | Novo Nordisk A/S | High moisture barrier container for medical liquid compositions |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3087491A (en) | 1958-03-14 | 1963-04-30 | Baxter Laboratories Inc | Parenteral solution equipment and method of making |
US3403064A (en) | 1963-09-12 | 1968-09-24 | Baxter Laboratories Inc | Method of forming a composite plastic container with an inner and outer seal |
CA1079231A (en) | 1976-12-16 | 1980-06-10 | Baxter Travenol Laboratories | Flexible collapsible container defining relatively rigid shoulder and base at opposite end |
US4212299A (en) | 1977-06-07 | 1980-07-15 | Toppan Printing Co., Ltd. | Container bag |
US4435135A (en) | 1981-04-03 | 1984-03-06 | Seaquist Valve Company | Pump assembly with improved seal |
DE3474006D1 (en) | 1983-08-01 | 1988-10-20 | Ausimont Usa | Coextrusion of thermoplastic fluoropolymers with thermoplastic polymers |
US4874386A (en) | 1986-12-05 | 1989-10-17 | Sta-Set Corporation | Fluid dispensing device |
US5000739A (en) | 1988-07-12 | 1991-03-19 | Pinewood Medical, Inc. | Programmable infusion pump |
US4857053A (en) | 1988-08-29 | 1989-08-15 | Dalton Michael J | Matrix septum |
US5205820A (en) | 1989-06-16 | 1993-04-27 | Science, Incorporated | Fluid delivery apparatus |
US5176634A (en) | 1990-08-02 | 1993-01-05 | Mcgaw, Inc. | Flexible multiple compartment drug container |
WO1993006158A1 (en) | 1991-09-27 | 1993-04-01 | Allied-Signal Inc. | High barrier pctfe film |
CH686881A5 (en) | 1993-12-17 | 1996-07-31 | Bieffe Medital Sa | Layered coextruded film for containers of parenteral solutions. |
JP3672617B2 (en) | 1994-05-25 | 2005-07-20 | 呉羽化学工業株式会社 | Polychlorotrifluoroethylene stretched film, method for producing the same, and package using the film |
JP3125636B2 (en) | 1994-08-10 | 2001-01-22 | 住友化学工業株式会社 | Packaging bag or packaging container |
DE19509632C1 (en) | 1995-03-17 | 1996-03-28 | Fresenius Ag | Implantable infusion pump |
US5928213A (en) * | 1996-05-13 | 1999-07-27 | B. Braun Medical, Inc. | Flexible multiple compartment medical container with preferentially rupturable seals |
US5944709A (en) | 1996-05-13 | 1999-08-31 | B. Braun Medical, Inc. | Flexible, multiple-compartment drug container and method of making and using same |
US5910138A (en) | 1996-05-13 | 1999-06-08 | B. Braun Medical, Inc. | Flexible medical container with selectively enlargeable compartments and method for making same |
US5874035A (en) | 1996-06-20 | 1999-02-23 | Alliedsignal Inc. | Highly oriented fluoropolymer films |
ATE215348T1 (en) * | 1996-12-23 | 2002-04-15 | Novo Nordisk As | A POLYMERIC CYCLIC HYDROCARBONS CONTAINER FOR STORING LIQUID MEDICATIONS |
US6530900B1 (en) | 1997-05-06 | 2003-03-11 | Elan Pharma International Limited | Drug delivery device |
US6306503B1 (en) | 1997-06-11 | 2001-10-23 | Alliedsignal Inc. | Multilayer fluoropolymer films with improved adhesion |
EP1445910A3 (en) | 1997-10-15 | 2005-03-02 | Nokia Corporation | Method of providing information in a communication system using a mobile telephone |
US6183460B1 (en) | 1998-01-22 | 2001-02-06 | Baxter International Inc. | Multi-use solution container having flaps |
US6287652B2 (en) | 1998-12-09 | 2001-09-11 | Color Prelude, Inc. | Fluid product sampler package with clear moisture vapor barrier film |
CA2299691C (en) | 1999-03-01 | 2011-07-12 | Johnson & Johnson Vision Care, Inc. | Package for medical device |
BE1012589A3 (en) | 1999-04-08 | 2000-12-05 | Solvay | Thermoplastic multi-structure. |
WO2001058506A2 (en) | 2000-02-10 | 2001-08-16 | Power Paper Ltd. | Drug delivery device and method |
US6572542B1 (en) | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
US6692472B2 (en) | 2000-05-04 | 2004-02-17 | Novo Nordisk A/S | Injection device, a preassembled dose setting and injection mechanism for an injection device, and a method of assembling an injection device |
JP2002028999A (en) | 2000-05-11 | 2002-01-29 | Mitsui Chemicals Inc | Gas barrier film laminate |
WO2005029242A2 (en) | 2000-06-16 | 2005-03-31 | Bodymedia, Inc. | System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability |
DE60120973T2 (en) | 2000-06-23 | 2007-02-15 | Honeywell International Inc. | HIGHLY HARDENING FILMS |
AU2001295350A1 (en) | 2000-11-03 | 2002-05-15 | Endoart S.A. | Implantable medical device for delivering a liquid |
ES2281457T3 (en) | 2000-11-09 | 2007-10-01 | Insulet Corporation | TRANSCUTANEOUS SUPPLY MEDIA. |
WO2003043494A1 (en) | 2001-11-23 | 2003-05-30 | Medit As | A cluster system for remote monitoring and diagnostic support |
US20030203141A1 (en) | 2002-04-25 | 2003-10-30 | Blum John B. | Blister package |
US6979316B1 (en) | 2002-05-23 | 2005-12-27 | Seedlings Life Science Ventures Llc | Apparatus and method for rapid auto-injection of medication |
FR2850027B1 (en) | 2003-01-21 | 2005-09-16 | Medex Sa | DEVICE FOR INJECTING MEDICAL LIQUID |
AU2003902187A0 (en) | 2003-05-08 | 2003-05-22 | Aimedics Pty Ltd | Patient monitor |
EP1677668B1 (en) | 2003-10-13 | 2010-07-14 | Novo Nordisk A/S | Apparatus and method for determining a physiological condition |
EP1525873A1 (en) | 2003-10-23 | 2005-04-27 | Novo Nordisk A/S | Container with septum member |
GB0405798D0 (en) | 2004-03-15 | 2004-04-21 | E San Ltd | Medical data display |
US8554480B2 (en) | 2004-03-25 | 2013-10-08 | Siemens Medical Solutions Usa, Inc. | Treatment data processing and planning system |
US8313308B2 (en) | 2004-03-26 | 2012-11-20 | Hospira, Inc. | Medical infusion pump with closed loop stroke feedback system and method |
WO2006021584A2 (en) | 2004-08-27 | 2006-03-02 | Novo Nordisk Health Care Ag | Purification of factor xiii polypeptides from biological materials |
JP2009522032A (en) | 2006-01-06 | 2009-06-11 | ノボ・ノルデイスク・エー/エス | Drug delivery device utilizing a collapsible reservoir |
CN101534704A (en) | 2006-11-14 | 2009-09-16 | 诺沃-诺迪斯克有限公司 | Adaptive hypoglycaemia alert system and method |
-
2004
- 2004-12-20 JP JP2006545920A patent/JP2007515235A/en not_active Withdrawn
- 2004-12-20 DE DE602004029496T patent/DE602004029496D1/en active Active
- 2004-12-20 AT AT04803041T patent/ATE483580T1/en not_active IP Right Cessation
- 2004-12-20 EP EP04803041A patent/EP1699629B1/en not_active Not-in-force
- 2004-12-20 WO PCT/DK2004/000890 patent/WO2005061222A1/en not_active Application Discontinuation
- 2004-12-20 CN CNA2004800385507A patent/CN1898087A/en active Pending
-
2006
- 2006-06-22 US US11/472,831 patent/US7807242B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54103184A (en) * | 1978-01-27 | 1979-08-14 | Toppan Printing Co Ltd | Bag for freezing preservation |
US5618913A (en) | 1985-08-30 | 1997-04-08 | Novo Nordisk A/S | Insulin analogues |
EP0254516A2 (en) | 1986-07-21 | 1988-01-27 | Novo Nordisk A/S | Novel Peptides |
EP0280534A2 (en) | 1987-02-25 | 1988-08-31 | Novo Nordisk A/S | Novel insulin derivatives |
WO1993006159A1 (en) * | 1991-09-27 | 1993-04-01 | Allied-Signal Inc. | Barrier film |
US5750497A (en) | 1993-09-17 | 1998-05-12 | Novo Nordisk A/S | Acylated insulin |
US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
EP0898466B1 (en) * | 1996-05-13 | 2001-12-12 | B. Braun Medical, Inc. | Flexible, multiple-compartment drug container and method of making |
DE19850607A1 (en) * | 1998-11-03 | 2000-05-04 | Rolf Siegel | Container for liquids containing biologically active substances, cells or cell organelles comprises a flexible container sealed within a rigid container |
EP1258234A1 (en) * | 2000-02-24 | 2002-11-20 | Mitsubishi Shoji Plastics Corporation | Plastic container for liquid medicine |
WO2005000580A1 (en) * | 2003-06-27 | 2005-01-06 | Novo Nordisk A/S | High moisture barrier container for medical liquid compositions |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Derwent World Patents Index; AN 1979-69127B * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007099120A1 (en) | 2006-02-28 | 2007-09-07 | Novo Nordisk A/S | A method and an apparatus for sterilizing packaging material |
US7972558B2 (en) | 2006-02-28 | 2011-07-05 | Novo Nordisk A/S | Method and an apparatus for sterilizing packaging material |
WO2008041644A1 (en) * | 2006-09-29 | 2008-04-10 | Daikin Industries, Ltd. | Fuel tank |
US11191722B2 (en) | 2013-04-03 | 2021-12-07 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
Also Published As
Publication number | Publication date |
---|---|
DE602004029496D1 (en) | 2010-11-18 |
JP2007515235A (en) | 2007-06-14 |
ATE483580T1 (en) | 2010-10-15 |
EP1699629B1 (en) | 2010-10-06 |
US7807242B2 (en) | 2010-10-05 |
EP1699629A1 (en) | 2006-09-13 |
US20070014951A1 (en) | 2007-01-18 |
CN1898087A (en) | 2007-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7807242B2 (en) | Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids | |
US8399078B2 (en) | Foil | |
USRE43331E1 (en) | Stabilized liquid protein formulations in pharmaceutical containers | |
EP3171868B1 (en) | Packaged acetaminophen injection solution preparation | |
KR100570537B1 (en) | Vitamin d solution holder and containers for transfusions | |
US20080311321A1 (en) | Multilayer Film With Septum Layer | |
JP4680454B2 (en) | Aseptic calcitonin preparation and method for producing the same | |
US20230201140A1 (en) | Phenylephrine premix formulations and uses thereof | |
US20230210865A1 (en) | Midazolam premix formulations and uses thereof | |
US9642828B2 (en) | Parenteral dosage form of amiodarone | |
US20230210722A1 (en) | Epinephrine premix formulations and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480038550.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004803041 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11472831 Country of ref document: US Ref document number: 2006545920 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004803041 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11472831 Country of ref document: US |